- Report
- June 2023
- 48 Pages
United States
From €573EUR$600USD£479GBP
- Report
- June 2023
- 48 Pages
United States
From €573EUR$600USD£479GBP
- Report
- June 2023
- 48 Pages
United States
From €573EUR$600USD£479GBP
- Report
- May 2023
- 48 Pages
United States
From €573EUR$600USD£479GBP
- Report
- May 2023
- 48 Pages
United States
From €573EUR$600USD£479GBP
- Report
- May 2023
- 48 Pages
United States
From €573EUR$600USD£479GBP
- Report
- May 2023
- 48 Pages
United States
From €573EUR$600USD£479GBP
- Report
- May 2023
- 48 Pages
United States
From €573EUR$600USD£479GBP
- Report
- May 2023
- 48 Pages
United States
From €573EUR$600USD£479GBP
- Report
- May 2023
- 48 Pages
United States
From €573EUR$600USD£479GBP
- Report
- May 2023
- 48 Pages
United States
From €573EUR$600USD£479GBP
- Report
- May 2023
- 48 Pages
United States
From €573EUR$600USD£479GBP
- Report
- April 2021
- 191 Pages
Global
€21011EUR$22,000USD£17,570GBP
- Report
- November 2020
- 49 Pages
Global
€1259EUR$1,318USD£1,053GBP
- Report
- May 2023
- 99 Pages
Global
From €3500EUR$3,926USD£3,029GBP
- Book
- April 2018
- 312 Pages
- Book
- October 2019
- 632 Pages
- Book
- April 2013
- 294 Pages
- Book
- October 2010
- 454 Pages
- Book
- September 2010
- 448 Pages

The Solid Tumor market within the context of Oncology is a highly competitive and rapidly evolving field. It is focused on the development of treatments for solid tumors, which are malignant tumors that form in the body's organs and tissues. These tumors can be caused by a variety of factors, including genetic mutations, environmental exposures, and lifestyle choices. Treatment options for solid tumors include surgery, chemotherapy, radiation therapy, and targeted therapies.
The Solid Tumor market is driven by the increasing prevalence of cancer, advances in technology, and the development of new treatments. Companies in this market are focused on developing innovative treatments and therapies to improve patient outcomes. Examples of companies in this market include AstraZeneca, Bristol-Myers Squibb, Eli Lilly, Merck, Novartis, Pfizer, and Roche. Show Less Read more